Initial Testing (Stage 1) of the Curaxin CBL0137 by the Pediatric Preclinical Testing Program

BACKGROUND: CBL0137 is a novel drug that modulates FACT (Facilitates Chromatin Transcription), resulting in simultaneous Nuclear factor-κB suppression, Heat shock factor 1 suppression and p53 activation. CBL0137 has demonstrated antitumor effects in animal models of several adult cancers and neurobl...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Pediatr Blood Cancer
Hoofdauteurs: Lock, Richard, Carol, Hernan, Maris, John M., Kolb, E. Anders, Gorlick, Richard, Reynolds, C. Patrick, Kang, Min H., Keir, Stephen T., Wu, Jianrong, Purmal, Andrei, Gudkov, Andrei, Kurmashev, Dias, Kurmasheva, Raushan T., Houghton, Peter J., Smith, Malcolm A.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2016
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5587189/
https://ncbi.nlm.nih.gov/pubmed/27650817
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.26263
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items